KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Free Cash Flow (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Free Cash Flow for 4 consecutive years, with -$61.3 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Free Cash Flow rose 52.93% year-over-year to -$61.3 million, compared with a TTM value of -$336.3 million through Dec 2023, down 10.45%, and an annual FY2025 reading of -$178.7 million, up 53.23% over the prior year.
  • Free Cash Flow was -$61.3 million for Q4 2023 at Ginkgo Bioworks Holdings, up from -$77.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$10.7 million in Q3 2021 and bottomed at -$170.7 million in Q4 2021.
  • Average Free Cash Flow over 4 years is -$79.2 million, with a median of -$77.9 million recorded in 2023.
  • The sharpest move saw Free Cash Flow soared 66.49% in 2022, then tumbled 368.63% in 2023.
  • Year by year, Free Cash Flow stood at -$78.8 million in 2020, then crashed by 116.7% to -$170.7 million in 2021, then rose by 23.72% to -$130.2 million in 2022, then surged by 52.93% to -$61.3 million in 2023.
  • Business Quant data shows Free Cash Flow for DNA at -$61.3 million in Q4 2023, -$77.9 million in Q3 2023, and -$87.1 million in Q2 2023.